

**(12) PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11)** Application No. **AU 200078822 B2**  
**(10)** Patent No. **764707**

(54) Title  
Peptide analogs as selective inhibitors of thrombin activation  
of protease activated receptor

(51)<sup>6</sup> International Patent Classification(s)  
C07K 007/06 C07K 007/08

(21) Application No: 200078822 (22) Application Date: 2000.08.17

(87) WIPO No: W001/12656

(30) Priority Data

(31) Number	(32) Date	(33) Country
09/375808	1999.08.17	US

(43) Publication Date : 2001.03.13  
(43) Publication Journal Date : 2001.05.17  
(44) Accepted Journal Date : 2003.08.28

(71) Applicant(s)  
Thromgen, Inc.; The Regents of the University of Michigan

(72) Inventor(s)  
Alvin H. Schmaier; Ahmed A. K. Hasan

(74) Agent/Attorney  
Griffith Hack,GPO Box 1285K,MELBOURNE VIC 3001

AU 200078822

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
WO 01/12656 A1

- (51) International Patent Classification: C07K 7/06, 7/08 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US00/40669
- (22) International Filing Date: 17 August 2000 (17.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/375,808 17 August 1999 (17.08.1999) US
- (71) Applicant (for all designated States except US): THROM- GEN, INC. [US/US]; 334 East Washington Street, Ann Arbor, MI 48104 (US), and The Regents of the University of Michigan, Wolverine Tower Room 2071, 3003 South State Street
- (72) Inventors; and (73) Inventors/Applicants (for US only): SCHMAIER, Alvin, H. [US/US]; 3308 The Glade, Ann Arbor, MI 48103 (US). HASAN, Ahmed, A., K., [US/US]; 5940 Dexter Ann Arbor Road, Scio Township, Dexter, MI 48130 (US).
- (74) Agent: HADDAWAY, Keith, G.; Venable, P.O. Box 34385, Washington, DC 20043-9998 (US).
- Published:  
With international search report.  
Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/12656 A1

(54) Title: PEPTIDE ANALOGS AS SELECTIVE INHIBITORS OF THROMBIN ACTIVATION OF PROTEASE ACTIVATED RECEPTOR 1

(57) Abstract: The invention relates to inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 with peptide analogs corresponding to those of Formula I and II, wherein Formula I is: Arg-Gly-Lys-Z<sub>1</sub>-Cys (SEQ ID NO: 43) wherein: Z<sub>1</sub> is any naturally occurring amino acid, excluding cysteine; and wherein Formula II is: Arg-Gly-Asp-Z<sub>2</sub>-Cys (SEQ ID NO: 44) wherein: Z<sub>2</sub> is any naturally occurring amino acid, excluding cysteine.

Ann Arbor MI 48109-1280  
USA

## PEPTIDE ANALOGS AS SELECTIVE INHIBITORS OF THROMBIN

### ACTIVATION OF PROTEASE ACTIVATED RECEPTOR 1

#### Field of Invention

This invention relates to the inhibition of  $\alpha$ - and  $\gamma$ -thrombin-induced cell activation.

#### Background of the Invention

5 All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art  
10 publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.

Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) (SEQ ID NO: 40) is a  
15 vasoactive peptide released from the precursor plasma kininogens by plasma and tissue kallikreins and other enzymes (Silva *et al.*, *Amer. J. Physiol.* 156: 261-274 (1949)). The parent proteins of bradykinin, high (HK) and low (LK) molecular weight kininogens were recognized to have the ability to inhibit  $\alpha$ - and  $\gamma$ -thrombin-induced platelet activation (Meloni *et al.*, *J. Biol. Chem.* 266, 6786 (1991); Puri *et al.*, *Blood* 77, 500 (1991)). Both  
20 low and high molecular weight kininogens have identical amino acid sequences from their amino-terminus through 12 amino acids beyond the carboxy-terminus of bradykinin. Both LK and HK share a common heavy chain (62 kDa), the bradykinin (BK) moiety (0.9 kDa), and the first 12 amino acids of the amino terminal portion of each of their "light chains" (Takagaki *et al.*, *J. Biol. Chem.* 260, 8601-8609 (1985); Kitamura *et al.*, *J. Biol. Chem.*,  
25 260, 8610-8617 (1985)). This identity corresponds to residues 1 through about residue 383. See Salveson *et al.*, *Biochem J.* 243, 429 (1986); Kellerman *et al.*, *Eur. J. Biochem.* 154, 471 (1986). The HK and LK kininogens diverge in the size of their light chains; the light chain of LK is 4 kDa; that of HK is 56 kDa. (Takagaki *et al.*, *supra*; Kitamura *et al.*, *supra*). The kininogens prevent thrombin-induced platelet activation without inhibiting  
30 thrombin's ability to hydrolyze a chromogenic substrate. Full-length kininogens prevent thrombin from binding to platelets. They do not interfere with thrombin's ability to proteolyze, i.e. cleave fibrinogen, which allows released fibrin monomer to make a fibrin clot. Thus, the prior art indicated that the kininogens' ability to inhibit thrombin activation

HAValma/Kcep/Specifications/08822-00.doc 22/02/02

of platelets was not due to their direct interaction with the thrombin molecule itself (Meloni *et al.*, *supra*; Puri *et al.*, *supra*).

The thrombin inhibitory activity of the kininogens appeared to be localized to an isolated domain 3 of the kininogens' heavy chain, because domain 3 retained all the

01  
02  
03  
04  
05  
06  
07  
08  
09  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2

thrombin inhibitory activity of the whole protein (Jiang *et al.*, *J. Biol. Chem.* 267, 3712 (1992)). The thrombin inhibitory activity of the kininogens was later found to be associated with domain 4, the bradykinin sequence, which was attached to the carboxyterminal end of isolated domain 3 prepared by proteolytic cleavage of whole LK

5 (Hasan *et al.*, *Circulation* 94, 517-528 (1996); Tayeh *et al.*, *J. Biol. Chem.* 269, 16318-16325 (1994)). The thrombin inhibitory region of domain 4, the bradykinin sequence, demonstrated a number of features. This sequence did not prevent thrombin from binding to platelets and it did not prevent the thrombin receptor activation peptide (TRAP), SFLLRN (SEQ ID NO: 46), from stimulating calcium mobilization and platelet

10 aggregation in platelets. This sequence from domain 4 prevented thrombin-activated platelets from losing an epitope to monoclonal antibody SPAN12. Monoclonal antibody SPAN12 is directed to the thrombin cleavage site on protease activated receptor 1 (PAR1) (Hasan *et al.*, *supra*; Vu *et al.*, *Cell* 64, 1057-1068 (1991); Brass *et al.*, *J. Biol. Chem.* 267, 13795-13798 (1992)). Monoclonal antibody SPAN12 was raised to the peptide

15 NATLDPRSFLLR (Asn-Ala-Thr-Leu-Asp-Pro-Arg-Ser-Phe-Leu-Leu-Arg) (SEQ ID NO: 41) (Brass *et al.*, *supra*). Further, bradykinin analog peptides prevented  $\alpha$ -thrombin from cleaving the peptide, NATLDPRSFLLR (Asn-Ala-Thr-Leu-Asp-Pro-Arg-Ser-Phe-Leu-Leu-Arg) (SEQ ID NO: 41), between arginine and serine, the identical place on PAR1 that thrombin cleaves to activate this receptor. Although there are a number of peptide analogs

20 of bradykinin that demonstrated thrombin inhibiting activity against platelet activation, the minimal sequences retaining this activity are the peptides, RPPGF (Arg-Pro-Pro-Gly-Phe) (SEQ ID NO: 39), RPPG (Arg-Pro-Pro-Gly) (SEQ ID NO: 45), and RPP (Arg-Pro-Pro). More recent investigations indicated that FITC-labeled (fluorescein isothiocyanate) RPPGF (Arg-Pro-Pro-Gly-Phe) (SEQ ID NO: 39) has the ability to directly bind to platelets (Hasan

25 *et al.*, *Thromb Haemost.* 82, 1182-1187 (1999)). These data indicated that the RPPGF (SEQ ID NO: 39) and related bradykinin analog peptides have the ability to bind to platelets to prevent thrombin-induced platelet activation.

The present invention relates to inhibition of thrombin-induced activation in human cells. Inhibition of thrombin activation of platelets can be either through an inhibitor of

30 thrombin directed to the thrombin molecule itself or an inhibitor directed to substrates of thrombin. Protease activated receptor 1 (PAR1) is a specific substrate of thrombin to which this class of inhibitor is directed. The present invention is directed to inhibition of this thrombin substrate on any cell that expresses PAR1. These cells include platelets, endothelial cells, smooth muscle cells, fibroblasts, neuronal cells, or any other cell that

contains this receptor. The present invention does not address inhibition of ADP-induced platelet activation as related to the thienopyridines class of agents, ticlopidine and clopidogrel. Similarly, the present invention does not address inhibition of platelet aggregation by preventing the formation of the heterodimeric complex of platelet glycoprotein IIb/IIIa (i.e. integrin  $\alpha_{IIb}\beta_3$ ). These compounds include the human-mouse chimeric monoclonal antibody 7E3c (ReoPro, abciximab), eptifibatide (Integrilin), and tirofiban (Aggrastat). This invention does not address aspirin inhibition of platelet activation by inhibition of platelet cyclooxygenase.

The following abbreviations have been used:

- 10 BK: bradykinin (SEQ ID NO: 40);
- D3: domain 3 of kininogens;
- D4: domain 4 of kininogen that is the bradykinin region;
- FITC: fluorescein isothiocyanate;
- HK: high molecular weight kininogen;
- 15 LK: low molecular weight kininogen;
- MAP4RPPGF: A four-branched peptide consisting of a  $\beta$ -alanine core with a single lysine attached at its amino terminal end followed by two additional lysines. Each lysine will then have two RPPGF (Arg-Pro-Pro-Gly-Phe) (SEQ ID NO: 39) peptides attached by the phenylalanine to each of the lysines;
- 20 NAT12: peptide sequence Asn-Ala-Thr-Leu-Asp-Pro-Arg-Ser-Phe-Leu-Leu-Arg (SEQ ID NO: 41) that spans the  $\alpha$ -thrombin cleavage site on the thrombin receptor;
- PARI: protease activated receptor 1;
- 25 PTCA: percutaneous transluminal coronary angioplasty;
- RPPGF: Arg-Pro-Pro-Gly-Phe (SEQ ID NO: 39);
- RPPG: Arg-Pro-Pro-Gly (SEQ ID NO: 45);
- RPP: Arg-Pro-Pro;
- SPAN12: a monoclonal antibody specific for the sequence (SEQ ID NO: 41) Asn-Ala-Thr-Leu-Asp-Pro-Ser-Phe-Leu-Leu-Arg that spans the  $\alpha$ -thrombin cleavage site on the thrombin receptor; and
- 30 Z: nomenclature for any naturally occurring amino acid.

### Summary of the Invention

The invention relates to a series of compounds to inhibit thrombin-induced platelet or human cell activation upon administering an effective amount of a peptide that inhibits thrombin activation of platelets or human cells, wherein said peptide has an amino acid

5 sequence of the formula:

(I) Arg-Gly-Lys-Z<sub>4</sub>-Cys (SEQ ID NO: 43)

wherein:

Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine.

The invention also comprises a series of compounds to inhibit thrombin-induced  
10 platelet or human cell activation upon administering an effective amount of a peptide that inhibits thrombin activation of platelets or human cells, wherein said peptide has an amino acid sequence of the formula:

(II) Arg-Gly-Asp-Z<sub>4</sub>-Cys (SEQ ID NO: 44)

wherein:

15 Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine.

The twenty amino acids (followed by their three letter abbreviations and one letter symbol) are set forth in TABLE VII below.

One embodiment of the invention comprises treating platelets or human cells with a compound of Formula I or Formula II to inhibit thrombin activation of platelets or  
20 activation of other cells, which express the thrombin receptor. Some of the preferred analogs include, RGKWC, RGKKC, RGKLC, RGKTC, RGKRC, RGDWC, RGDFC, RGDEC, and RGDNC (SEQ ID NOS 5, 14, 1, 2, 3, 20, 21, 22 & 32, respectively).

An object of administration of these peptides of Formulae I and II to cells is to prevent thrombosis, *i.e.*, an occlusion of a vessel due to formation of a platelet-rich, fibrin-rich or a mixed platelet-fibrin thrombus. Accordingly, the invention relates to the foregoing analogs, and to the contact of these analogs with platelets and human cells which express the thrombin receptor to prevent thrombosis.

For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.

### Description of the Figures

Figure 1 illustrates the effect of the peptide RGKWC (Arg-Gly-Lys-Trp-Cys) (SEQ ID NO: 5) on  $\gamma$ -thrombin-induced platelet aggregation in platelet-rich plasma. The figure shows aggregation tracings. In the upper left, 70 nM  $\gamma$ -thrombin induced a full


H:\Valma\Keep\Specifications\78622-00.doc 22/02/02

aggregation. One mM RPPGF (Arg-Pro-Pro-Gly-Phe) (SEQ ID NO: 39), a control aggregation, abolished thrombin-induced platelet aggregation. Aggregation returned at 0.25 mM RPPGF (SEQ ID NO: 39). In comparison, 1 mM RGKWC (Arg-Gly-Lys-Trp-

39

39

39



H:\Vlm\Keep\Specifications\78822-00.doc 22/02/02



Cys) (SEQ ID NO: 5) also abolished  $\gamma$ -thrombin-induced platelet aggregation. At 0.125 mM RGKWC (SEQ ID NO: 5), thrombin-induced platelet aggregation returned.

Figure 2 illustrates the effect of the peptide RGKWC (Arg-Gly-Lys-Trp-Cys) (SEQ ID NO: 5) on  $\alpha$ -thrombin-induced calcium mobilization in fibroblasts. In the upper left, 2 nM  $\alpha$ -thrombin induces a robust level of  $\text{Ca}^{2+}$  mobilization in these fibroblasts. Using RGKWC (SEQ ID NO: 5) at 0.2 mM,  $\alpha$ -thrombin-induced calcium mobilization is abolished. As the concentration of RGKWC (SEQ ID NO: 5) decreased, the ability of thrombin to induce  $\text{Ca}^{2+}$  mobilization returned. At 12.5  $\mu\text{M}$  RGKWC (SEQ ID NO: 5),  $\alpha$ -thrombin overcame the inhibitory effect of the peptide.

Figure 3 illustrates the effect of the peptide RGDWC (Arg-Gly-Asp-Trp-Cys) (SEQ ID NO: 20) on  $\gamma$ -thrombin-induced platelet aggregation. Seventy nM  $\gamma$ -thrombin induced a full level of platelet aggregation. One mM RPPGF (Arg-Pro-Pro-Gly-Phe) (SEQ ID NO: 39) completely abolished  $\gamma$ -thrombin-induced platelet aggregation. RGDWC (Arg-Gly-Asp-Trp-Cys) (SEQ ID NO: 20) (0.2 mM) completely abolished  $\gamma$ -thrombin-induced platelet aggregation. At 6.25  $\mu\text{M}$  RGDWC (SEQ ID NO: 20),  $\gamma$ -thrombin-induced platelet aggregation returned.

Figure 4 illustrates the effect of RGDWC (Arg-Gly-Asp-Trp-Cys) (SEQ ID NO: 20) on  $\alpha$ -thrombin-induced  $\text{Ca}^{2+}$  mobilization. Four nM  $\alpha$ -thrombin induced a full  $\text{Ca}^{2+}$  mobilization. (SEQ ID NO: 20) RGDWC at 0.2 mM almost had no effect on thrombin-induced  $\text{Ca}^{2+}$  mobilization.

Figure 5 illustrates the effect on ADP-induced platelet aggregation of various peptides that interfere with thrombin-induced platelet aggregation. Four and a half  $\mu\text{M}$  ADP induced a full aggregation response. Peptides RPPGF (Arg-Pro-Pro-Gly-Phe) (SEQ ID NO: 39), MAP4RPPGF, and RGKWC (Arg-Gly-Lys-Trp-Cys) (SEQ ID NO: 5) at 1 mM did not inhibit ADP-induced platelet aggregation. Alternatively, RGDWC (Arg-Gly-Asp-Trp-Cys) (SEQ ID NO: 20) at 0.5 mM abolished ADP-induced platelet aggregation.

Figure 6 examines the ability of biotinylated-peptide NATLDPRSFLLR (biotin-NAT12) (SEQ ID NO: 41) binding to peptides RPPGF (Arg-Pro-Pro-Gly-Pro) (SEQ ID NO: 39), MAP4RPPGF, RGDWC (Arg-Gly-Asp-Trp-Cys) (SEQ ID NO: 20), or RGKWC (Arg-Gly-Lys-Trp-Cys) (SEQ ID NO: 5). Each of these peptides at 10  $\mu\text{g}/\text{ml}$  was coupled to a microtiter plate by incubating them in 0.1 M  $\text{Na}_2\text{CO}_3$ , pH 9.6 buffer. Biotin-NAT12 was incubated with the plate and the level of bound biotinylated peptide was determined.

Table I is a tabulation of the RGKO<sub>4</sub>C (SEQ ID NO: 43) sublibrary and the influence of each peptide on  $\gamma$ -thrombin-induced platelet aggregation in platelet-rich plasma. The numbers in the column under "Fold Increase in Aggregation Inhibition Over RPPGF (SEQ ID NO: 39)" represent the increase in the degree of inhibition of thrombin-induced platelet aggregation as compared to RPPGF (SEQ ID NO: 39) at 0.2 mM.

Table II is a tabulation of the RGKO<sub>4</sub>C (SEQ ID NO: 43) sublibrary and the influence of each peptide on  $\gamma$ -thrombin-induced calcium mobilization in fibroblasts. The numbers in the column under " $\text{Ca}^{2+}$  % Inhibition" represent the degree of inhibition of thrombin-induced calcium mobilization by the peptide.

Table III is a tabulation of the RGKO<sub>4</sub>C (SEQ ID NO: 43) sublibrary and the affinity of biotin-NAT12 (SEQ ID NO: 41) to bind to each of the peptides coupled to microtiter plate wells. The numbers in the column under "Level of Binding to Biotin-NAT12" represent the increased degree of binding of biotin-NAT12 to the peptide listed as compared to RPPGF (SEQ ID NO: 39), the latter of which is given an arbitrary binding level of 1.

Table IV is a tabulation of the RGDO<sub>4</sub>C (SEQ ID NO: 44) sublibrary and the influence of each peptide on  $\gamma$ -thrombin-induced platelet aggregation. The numbers in the column under "Fold Increase in Aggregation Inhibition Over RPPGF (SEQ ID NO: 39)" represent the increase in the degree of inhibition of thrombin-induced platelet aggregation as compared to RPPGF (SEQ ID NO: 39) at 0.2 mM.

Table V is a tabulation of the RGDO<sub>4</sub>C (SEQ ID NO: 44) sublibrary and the influence of each peptide on  $\gamma$ -thrombin-induced calcium mobilization in fibroblasts. The numbers in the column under " $\text{Ca}^{2+}$  % Inhibition" represent the degree of inhibition of thrombin-induced calcium mobilization by the peptide.

Table VI is a tabulation of the RGDO<sub>4</sub>C (SEQ ID NO: 44) sublibrary and the affinity of biotin-NAT12 to bind to each of the peptides coupled to microtiter plate wells. The numbers in the column under "Level of Binding to Biotin-NAT12" represent the increased degree of binding of biotin-NAT12 to the peptide listed than to RPPGF (SEQ ID NO: 39), the latter of which is given an arbitrary binding level of 1.

#### Detailed Description of the Invention

The invention relates to the peptide analogs of Formulae I and II above.

Peptides of the invention are produced by conventional solid phase peptide synthesis techniques using automated synthesis. Each reference cited herein is incorporated by

reference as if each were individually incorporated by reference. The segments of interest may also be prepared by recombinant DNA techniques. Accordingly, the method of the present invention can be implemented with polypeptides prepared by peptide synthetic methods or by recombinant techniques.

- 5 In accordance with the present invention naturally occurring or synthetic amino acids having the general formula  $\text{CO}_2(\text{RCHCH}(\text{NH}_3)^+)$  are produced by addition of the group to either the carboxyl or amino terminus of a peptide comprising the core sequence in order to form chain expansion analogs. The peptides of Formula I and Formula II
- 10 comprise at most ten (10) amino acids in sequence. Preferably, the peptide compound and the segment comprise five amino acids in sequence. In accordance with the preferred synthesis, the synthetic peptide combinatorial libraries (SPCL) of  $\text{H-R-O}_2\text{-X-X-C-NH}_2$ ,  $\text{H-R-X-O}_3\text{-X-C-NH}_2$ ,  $\text{H-R-X-X-O}_4\text{-C-NH}_2$ ,  $\text{H-R-G-O}_3\text{-X-C-NH}_2$ , and  $\text{H-R-G-X-O}_4\text{-C-NH}_2$  in positional scanning format and  $\text{H-R-G-K-O}_4\text{-C-NH}_2$  and  $\text{H-R-G-D-O}_4\text{-C-NH}_2$  (SEQ ID NOS 43 & 44, respectively) in iterative format were synthesized according to the published
- 15 method (Houghten *et al.*, *BioTechniques* 13(3): 412-421(1992).  $\text{O}_2$ ,  $\text{O}_3$ , and  $\text{O}_4$  are the defined positions in which one of any naturally occurring amino acid, except cysteine, is placed. The cysteine was excluded to prevent dimer or oligomer formation. "X" represents the equimolar mixture (Houghten *et al.*, *BioTechniques* 13(3): 412-421(1992)) of the naturally occurring amino acids, except cysteine. Here again, cysteine was omitted to
- 20 avoid dimerization or oligomerization.

- The first positional scanning library was composed of three sublibraries ( $\text{H-R-O}_2\text{-X-X-C-NH}_2$ ,  $\text{H-R-X-O}_3\text{-X-C-NH}_2$ , and  $\text{H-R-X-X-O}_4\text{-C-NH}_2$ ), each composed of 19 separate peptide mixtures, which represent a total of  $19^3$  or 6859 individual peptides. Each sublibrary contained the same individual sequence but grouped in a different way. The
- 25 screening of the first library, i.e., all three first sublibraries, provided the information about the most effective amino acid at each position and the relative specificity of each position. From the screening data using the three assays (the platelet aggregation assay, the calcium mobilization assay and the biotin-NAT12 binding assay) described more fully within, it appeared that glycine (G) at the second position conferred the most specific inhibitory
- 30 activity (i.e. no other amino acids were found to be as active as glycine at this position). There was no clear specific amino acid candidate for the third or fourth position.

With this information, a second library was synthesized in positional scanning format having the first and second position defined as arginine (R) and glycine (G), respectively. The second library was synthesized following the same method of the SPCL

synthesis referenced above. This second library was composed of two sublibraries (H-R-G-O<sub>3</sub>-X-C-NH<sub>2</sub> and H-R-G-X-O<sub>4</sub>-C-NH<sub>2</sub>), each composed of 19 separate peptide mixtures, which represented a total of 19<sup>2</sup> or 361 individual peptides. Again, O<sub>3</sub>, O<sub>4</sub>, and X are used as described above for the first library. Screening these two sublibraries revealed that two amino acids, lysine (K) and aspartic acid (D) were most active and relatively specific residues for the third position after arginine and glycine. There was no clear candidate residue for the fourth position. In order to determine the fourth positional moiety, a third library was synthesized in iterative format according to published methods. (Houghton, *et al.*, *BioTechniques* 13(3): 412-421 (1992)). This library was composed of two sublibraries: H-R-G-K-O<sub>4</sub>-C-NH<sub>2</sub> and H-R-G-D-O<sub>4</sub>-C-NH<sub>2</sub> (SEQ ID NOS 43 & 44, respectively). Each library consisted of 19 individual peptides with a total of 38 individual peptides. The O<sub>4</sub> was replaced with each natural amino acid, except cysteine.

This invention is directed to a method for preventing thrombosis using peptide analogs that act as selective antithrombins. These peptide analogs are selective antithrombins because they are able to inhibit human  $\alpha$ -thrombin and  $\gamma$ -thrombin from activating platelets or other cells by cleaving PAR1 at or near its thrombin cleavage site to prevent thrombin induced stimulus-response coupling and activation of platelets and other cells. The relative concentrations of thrombin to platelets used to induce platelet activation or aggregation ranged from about 0.05 to about 3 nM of  $\alpha$ -thrombin or about 15 to about 70 nM of  $\gamma$ -thrombin. Compounds of Formula I and Formula II are a first generation of compounds that achieve selectivity in inhibiting thrombin activation by being directed to a substrate of thrombin rather than the enzyme itself. Most known thrombin inhibitors, hirudin, hirulog, hirugin, argatroban, etc., interfere with  $\alpha$ -thrombin's action by blocking all of its proteolytic activity. Use of these known proteolytic inhibitors to block  $\alpha$ -thrombin activation of platelets and other cells expressing PAR1 may result in excessive anticoagulation, hemorrhage, and interference with other important biologic activities such as mitogenesis and cell proliferation. The peptide analogs utilized in the present method allow for inhibition of thrombin induced platelet or other cell stimulus-response coupling and activation mediated by one substrate of thrombin, PAR1, without interfering with other  $\alpha$ -thrombin activities such as activation of factors V and XIII.

We have found that the peptides described herein inhibit thrombin cleavage of the thrombin receptor (PAR1) which is expressed on platelets, fibroblasts and other human cells. Thus, we have found that the peptides described here have the ability to inhibit

thrombin-induced platelet activation by blocking cleavage of PAR1 and subsequent activation of platelets by exposure of the new amino terminus of the cleaved receptor. Administration of a peptide analog described herein comprises a method for inhibiting thrombin-induced activation of platelets, endothelial cells, brain cells, fibroblasts, smooth muscle cells, or other cells that contain the PAR1 receptor for thrombin. This function inhibits platelet thrombus formation and other activities mediated by the thrombin receptor.

The peptide analogs described here do not inhibit platelet activation by the same mechanism as intact kininogens or isolated domain 3. One mM peptide analogs do not block  $^{125}$ I- $\alpha$ -thrombin binding to platelets, as do molar excess purified HK, LK, or isolated domain 3. We have found that these peptide analogs:

- 1) block  $\alpha$ -thrombin-induced calcium mobilization in fibroblasts;
- 2) block  $\gamma$ -thrombin-induced platelet aggregation; and
- 3) directly bind biotin-NAT12.

According to one embodiment of the invention, these peptide analogs represent an amino acid substitution in the fourth position of the parent peptide that has the sequence RGKZ<sub>4</sub>C (Arg-Gly-Lys-Z<sub>4</sub>-Cys) (SEQ ID NO: 43). The fourth position can be any naturally occurring amino acid, except cysteine. In a further embodiment of the invention, these peptide analogs represent an amino acid substitution in the fourth position of the parent peptide that have the sequence RGDZ<sub>4</sub>C (Arg-Gly-Asp-Z<sub>4</sub>-Cys) (SEQ ID NO: 44). The fourth position can be any naturally occurring amino acid, except cysteine.

#### **I. Preparation of Peptide Analogs that Intefere with Thrombin-Induced Platelet Aggregation**

##### **A. Assays to Screen Combinatorial Libraries**

Three assays were developed to screen peptides produced by combinatorial libraries:

##### **1. Platelet Aggregation**

Fresh whole blood was collected and mixed with 0.013 M sodium citrate and platelet-rich plasma was prepared according to the method of Meloni *et al.*, *J. Biol. Chem.* 266, 6786 (1991). Platelet-rich plasma with a normalized platelet count between 2-2.5 X 10<sup>8</sup> platelets/ml was added to a cuvette of an aggregometer (Chronlog Corp., Havertown, PA), standardized using the protocol of Meloni *et al.*, *supra*. Peptides to be examined were added to the cuvette and the mixture stabilized for a few moments. Once the baseline was

stabilized,  $\gamma$ -thrombin (10-70 nM) (Haematologic Technologies, Essex Junction, VT) was added to determine the minimal concentration of the agonist necessary to achieve full platelet aggregation. All investigations with peptides were performed using threshold concentrations of  $\gamma$ -thrombin. Aggregation was allowed to proceed for 5 minutes before  
5 stopping. When ADP-induced platelet aggregation studies were performed, 1-5  $\mu$ M ADP (Sigma) was added to the cuvette containing platelet-rich plasma.

As shown in Figure 1, 70 nM  $\gamma$ -thrombin induced a full platelet aggregatory response. The aggregation response was abolished by 0.5-1 mM RPPGF (SEQ ID NO: 39). At 0.25 mM (SEQ ID NO: 39) RPPGF,  $\gamma$ -thrombin-induced platelet aggregation  
10 returned. This inhibitory response was compared to that seen with RGKWC (SEQ ID NO: 5). At 0.25-1 mM (SEQ ID NO: 5) RGKWC,  $\gamma$ -thrombin-induced platelet aggregation was completely inhibited. At 0.125 mM (SEQ ID NO: 5) RGKWC,  $\gamma$ -thrombin-induced platelet aggregation returned to levels seen without any inhibitor. Table I shows a list of  
15 RGKO<sub>4</sub>C (SEQ ID NO: 43) peptides which inhibit  $\gamma$ -thrombin-induced platelet aggregation. The most potent to least potent inhibitors of  $\gamma$ -thrombin-induced platelet aggregation are RGKLC, RGKTC, RGKRC, RGKIC, RGKWC, RGKYC, and RGKMC (SEQ ID NOS 1-7, respectively) in decreasing order.

Figure 3 shows results with the RGDWC (SEQ ID NO: 20) peptide on  $\gamma$ -thrombin-induced platelet aggregation. Seventy nM  $\gamma$ -thrombin induced threshold platelet  
20 aggregation. One mM RPPGF (SEQ ID NO: 39) abolished  $\gamma$ -thrombin-induced platelet aggregation. Peptide RGDWC (SEQ ID NO: 20) inhibited  $\gamma$ -thrombin-induced platelet aggregation down to a concentration of 25  $\mu$ M. At 6.25  $\mu$ M RGDWC (SEQ ID NO: 20),  $\gamma$ -thrombin-induced platelet aggregation returned to normal. Table IV lists all the RGDO<sub>4</sub>C (SEQ ID NO: 44) peptides from most potent to weakest that inhibit  $\gamma$ -thrombin-induced  
25 platelet aggregation.

Figure 5 compares the ability of RGKWC (SEQ ID NO: 5) and RGDWC (SEQ ID NO: 20) peptides on ADP-induced platelet aggregation. Untreated platelets had full platelet aggregation with 4.5  $\mu$ M ADP. One mM RPPGF (SEQ ID NO: 39), MAP4RPPGF (MaP<sub>4</sub>), and RGKWC (SEQ ID NO: 5) did not inhibit ADP-induced platelet aggregation.  
30 Alternatively, RGDWC (SEQ ID NO: 20) at  $\geq 0.5$  mM completely inhibited ADP-induced platelet aggregation. These data indicated that the RGKO<sub>4</sub>C (SEQ ID NO: 43) group of compounds was more specifically directed to thrombin-induced platelet aggregation than the RGDO<sub>4</sub>C (SEQ ID NO: 44) group of compounds which could be influencing thrombin-

induced platelet aggregation, but also were influencing ADP-induced platelet aggregation. It is believed that the RGD-based compounds partially inhibit thrombin-induced platelet aggregation by blocking the final common pathway of platelet aggregation, i.e., the binding of fibrinogen to the heterodimeric complex of glycoprotein IIb/IIIa, i.e.,  $\alpha_{IIb}\beta_3$  integrin.

## 2. Calcium Mobilization Assay

The second assay developed to assess peptides from the combinatorial libraries uses inhibition of  $\alpha$ -thrombin-induced calcium mobilization in fibroblasts. Normal human lung fibroblasts (NHLF) were purchased from Clonetics, San Diego, CA, an affiliate of Bio-Wittaker, Walkersville, MD. The cytoplasmic free  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) was measured using the fluorescent  $\text{Ca}^{2+}$  indicator fura-2 (Molecular Probes, Inc., Eugene, OR). Suspension of fibroblasts in Hepes-Tyrod's buffer were loaded with fura-2 by incubation at  $37^\circ\text{C}$  with  $2\ \mu\text{M}$  fura-2/acetoxymethyl ester for 45 minutes according to the method of Rasmussen *et al.*, *J. Biol. Chem.* 268, 14322 (1993). The labeled fibroblasts were separated from excess probe by washing by centrifugation at 1000 rpm (180xg). Aliquots of the labeled fibroblasts were transferred into a quartz cuvette with a magnetic stirrer, which was then placed in a thermostatically controlled chamber at  $37^\circ\text{C}$  in a fluorescence spectrophotometer (Perkin-Elmer LS50B spectrofluorometer, Chicago, IL). Reagents, test peptide (from 0.2 mM to effective lower concentration), and  $\alpha$ -thrombin (2-4 nM), were sequentially added directly to the cuvette. The excitation wavelengths varied between 340 and 380 nm. Fluorescence was measured by recording emitted light at 510 nm as reported by Fisher *et al.*, *Mol. Pharm.* 35, 195 (1989). The minimum emission was determined on a solubilized fibroblast sample in the presence of 10 mM EDTA; maximum emission was determined on the same sample with 10 mM  $\text{Ca}^{2+}$  added. The intrafibroblast free  $\text{Ca}^{2+}$  concentration was calculated by the method of Grykiewicz *et al.*, *J. Biol. Chem.* 260, 3440 (1985). The ratio of the fluorescence readings was calculated as  $R = 340/380$  nm and processed according to the equation  $[\text{Ca}^{2+}]_i = K_D((R - R_{\min})/(R_{\max} - R))(S_D/S_{D2})$  to determine the intrafibroblast free  $\text{Ca}^{2+}$  concentration. The  $K_D$  for fura-2 was assumed to be 224 nM.  $R_{\max}$  and  $R_{\min}$  are the maximum and minimum fluorescence ratios measured at the end of the experiment, respectively;  $S_D$  and  $S_{D2}$  are the fluorescence values at 380 nm in the absence and presence of saturating  $[\text{Ca}^{2+}]$ , respectively. The reaction was monitored for 3-5 minutes. As shown in Figure 2, peptide RGKWC (SEQ ID NO: 5) blocked 2 nM  $\alpha$ -thrombin-induced  $\text{Ca}^{2+}$  mobilization in fibroblasts at concentrations  $\geq 50\ \mu\text{M}$ . Table II

lists all the RGKO<sub>4</sub>C (SEQ ID NO: 43) peptides from the most potent to the least potent inhibitor of thrombin-induced Ca<sup>2+</sup> mobilization. The table shows, in decreasing potency, the percent inhibition of thrombin-induced calcium mobilization using 0.2 mM of each of the peptides. The eight most potent inhibitors in decreasing order were : RGKWC, 5 RGKKC, RGKRC, RGKHC, RGKPC, RGKQC, RGKTC, and RGKDC (SEQ ID NOS 5, 14, 3, 13, 16, 17, 2, & 9, respectively). In Figure 4, peptide (SEQ ID NO: 20) RGDWC at 0.2 mM inhibited 31% of 4 nM  $\alpha$ -thrombin-induced Ca<sup>2+</sup> mobilization in fibroblasts. Table V shows the list of RGDO<sub>4</sub>C (SEQ ID NO: 44) peptides from the most potent to least potent inhibitors of thrombin-induced Ca<sup>2+</sup> mobilization. The table shows, in decreasing 10 potency, the percentage of inhibition of thrombin-induced calcium mobilization using 0.2 mM of each of the peptides. The seven most potent peptides in decreasing order of potency include: RGDNC, RGDWC, RGDFC, RGDKC, RGDMC, RGDYC, and RGDAC (SEQ ID NOS 32, 20, 21, 29, 24, 35, & 37, respectively).

### 3. Biotin-NAT12 binding assay to peptide analogs

15 A third assay was developed to ascertain the ability of biotin-NAT12 (NATLDPRSFLLR) (SEQ ID NO: 41) to directly bind to peptides linked to microtiter plates. In this assay, peptide analogs were linked to microtiter plate cuvette wells by incubation of the peptide in 0.1 M Na<sub>2</sub>CO<sub>3</sub>, pH 9.6 buffer overnight at 4°C. After coupling the peptide to the cuvette well, the wells were dumped and each well was blocked with 1% 20 bovine serum albumin in 0.01 M Na<sub>3</sub>PO<sub>4</sub>, 0.15 M NaCl, at pH 7.4. After incubation for 1 hour, the wells were dumped and washed three times with PBS-Tween. The wells were then incubated with biotin-NAT12. The amount of biotin-NAT12 bound was determined by adding streptavidin-peroxidase followed by adding turbo TMB (Pierce).

Figure 5 shows that peptide RGKWC (SEQ ID NO: 5) binds to a greater extent than 25 peptide (SEQ ID NO: 20) RGDWC. The level of binding of RGKWC (SEQ ID NO: 5) was greater than RPPGF (SEQ ID NO: 39). However, its level of binding was less than that seen with the multiple branched peptide MAP4RPPGF. Table III shows the RGKO<sub>4</sub>C (SEQ ID NO: 43) peptides that bind biotin-NAT12. In decreasing order of binding level, these peptides include: RGKSC, RGKMC, RGKHC, RGKKC, RGKFC, RGKLC, 30 RGKWC, and RGKVC (SEQ ID NOS 18, 7, 13, 14, 11, 1, 5 & 19, respectively). Table VI shows the RGDO<sub>4</sub>C (SEQ ID NO: 44) peptides that bind biotin-NAT12. The best RGDO<sub>4</sub>C (SEQ ID NO: 44) peptide (RGDSC) (SEQ ID NO: 34) to bind biotin-NAT12 was equivalent to the ability of RGKWC (SEQ ID NO: 5) to bind biotin-NAT12. The best to least RGDO<sub>4</sub>C (SEQ ID NO: 44) peptides to bind biotin-NAT12 listed in Table VI are:



RGDSC, RGDGC, RGDQC, RGDEC, RGDIC, RGDPC, RGDDC, and RGDYC (SEQ ID NOS 34, 28, 23, 22, 36, 38, 27 & 35, respectively). A solid phase peptide-peptide binding assay was used to determine biotin-NAT12 binding to library peptides. Test peptides in 0.1 M Na<sub>2</sub>CO<sub>3</sub>, pH 9.6 buffer, at 10 µg/well in 50 µl volume, were coupled to microtiter plate wells by overnight incubation at 4°C. After incubation, the contents of the wells were discarded and the wells were washed with a pH 7.4 buffer containing 0.01 M Na<sub>3</sub>PO<sub>4</sub>, 0.15 M NaCl, and 0.01% Tween 20. After blocking each well with 1% radioimmunoassay grade bovine serum albumin, the linked peptides were incubated with 100 µl of 100 µM biotin-NAT12 for 1 hour at 37°C. After incubation, the contents of the wells were dumped and the wells were washed three times (100 µl/well each time) with the buffer identified above. Each well then was incubated with 100 µl of 2 µg/ml solution of Immuno-Pure streptavidin horseradish peroxidase conjugate (Pierce Chemical Co., Rockville, IL) for 1 hour at room temperature. The contents of the wells were discarded and the wells were washed three times as described above. The wells were then incubated with 100 µl of peroxidase-specific fast reacting substrate, turbo-3,3',5,5'-tetramethylbenzidine (turbo-TMB, Pierce) for 5 minutes at room temperature and the developing color reaction was stopped by the addition of 100 µl of 1 M phosphoric acid. The absorbance was measured at 450 nm using a Microplate Auto Reader EL311 (Bio-Tek, Winooski, VT). The extent of biotin-NAT12 binding to test peptides from the libraries was assessed by the degree of absorbance displayed.

#### **B. Preparation of Peptide Combinatorial Library**

Three successive combinatorial libraries were prepared to obtain the peptide analogs that are contained herein. The first library started with the peptide RPPGF (Arg-Pro-Pro-Gly-Phe) (SEQ ID NO: 39). Investigations showed that an alanine substitution in the peptide at position 1 at the amino terminal end resulted in marked loss of thrombin inhibitory activity. Alternatively, substitution in the fifth position at the carboxyterminal end of a cysteine for a phenylalanine did not result in any loss of activity. Since cysteine in this fifth position promoted binding of the peptides to plastic plates, all subsequent peptides had cysteine placed at this position.

The initial positional peptide combinatorial library consisted of H-RO<sub>2</sub>XXC-NH<sub>2</sub>, H-RXO<sub>3</sub>XC-NH<sub>2</sub>, and H-RXXO<sub>4</sub>C-NH<sub>2</sub>, where O<sub>2</sub>, O<sub>3</sub>, or O<sub>4</sub> represents all L-amino acids from A to Y, except cysteine, and X is an equimolar mixture of L-amino acids from A to

Y, except cysteine (Houghten *et al.*, *BioTechniques* 13(3): 412-421(1992)). Investigations revealed that a glycine in the second position produced a peptide(s) with the best ability to inhibit thrombin-induced platelet aggregation, to inhibit thrombin-induced calcium mobilization, and to bind biotin-NAT12. A second peptide combinatorial library was designed to examine the third and fourth position of this sequence. Peptides H-RGO<sub>3</sub>XC-NH<sub>2</sub> and H-RGXO<sub>4</sub>C-NH<sub>2</sub> were prepared where O<sub>3</sub> and O<sub>4</sub> were all L-amino acids from A to Y, except cysteine, and X was an equimolar mixture of L-amino acids from A to Y, except cysteine. Investigations revealed that a lysine or aspartic acid in the third position produced peptides with the best ability to inhibit thrombin-induced platelet aggregation, inhibit thrombin-induced calcium mobilization, and bind biotin-NAT12. A third library was prepared where the third positions were fixed as a lysine or aspartic acid: H-RGKO<sub>4</sub>C-NH<sub>2</sub> and H-RGDO<sub>4</sub>C-NH<sub>2</sub> (SEQ ID NOS 43 & 44, respectively), where O<sub>4</sub> is all L-amino acids except cysteine. The peptides from this third combinatorial library are the peptide analogs being described herein.

A standard solid phase automated peptide synthesis was utilized to prepare the peptide libraries. The synthetic peptide libraries were prepared using methylbenzhydrylamine (MBHA) polystyrene resin and standard *t*-Boc chemistry in combination with simultaneous multiple peptide synthesis (SMPS) (Houghten *et al.*, *Nature*. 354, 84-86 (1991); Houghten *et al.*, *BioTechniques*. 13, 412-421 (1992); Dooley *et al.*, *Science*. 266, 2019-2022 (1994)). A peptide synthesis resin was prepared that assures equimolarity of the peptides on the resin (Houghten *et al.*, *BioTechniques*. 13, 412-421 (1992)). Nineteen porous polypropylene packets, each containing 4.65 mmol of MBHA resin, were coupled to each of the protected *N*- $\alpha$ -*t*-Boc amino acids of interest (Houghten *et al.*, *BioTechniques*. 13, 412-421 (1992)). Cysteine was excluded from the coupling mixture. In all cases the coupling reactions were > 99.9% complete as assessed by picric acid or ninhydrin tests (Gisin *Analytica chim. Acta*. 58, 248-249, (1972); Kaiser *et al.*, *Analyt. Biochem.* 34, 595-598 (1970)). The resulting resins from each packet were combined and thoroughly mixed. There were approximately 4000 beads per mg of resin. The resin mixture was then separated into 19 portions of equal weight which were then placed into porous polypropylene packets, followed by *N*- $\alpha$ -*t*-Boc protecting group removal and neutralization of the resulting amine TFA salts. The resin packets were then reacted with solutions of the individual activated amino acids to yield the various peptide combinations. The peptide mixtures were deprotected and then cleaved from their respective resins using low-high hydrogen fluoride (HF) (Cuervo *et al.*, *Peptide Res.* 1, 81-

- 14 -

86 (1991); Tam, J.P., *et al.*, *J. Am. Chem. Soc.* 105, 6442-6455 (1983); Houghten *et al.*, *Int. J. Peptide Protein Res.* 27, 673-678 (1986)) in a multiple HF cleavage apparatus (Multiple Peptide Systems, San Diego, CA). Extraction of the individual peptide mixtures was carried out with H<sub>2</sub>O or dilute acetic acid and the solutions lyophilized.

5

Table I

**Effect of RGKQ<sub>4</sub>C (SEQ ID NO: 21) Peptide Sublibrary on  
Thrombin-Induced Platelet Aggregation**

10

	Peptide	Fold Increase in Aggregation	SD
		Inhibition over RPPGF(SEQ ID NO: 39)	
	RGKLC (SEQ ID NO: 1)	7.7	7.2
	RGKTC (SEQ ID NO: 2)	4.4	4.4
15	RGKRC (SEQ ID NO: 3)	2.5	
	RGKIC (SEQ ID NO: 4)	1.3	
	RGKWC (SEQ ID NO: 5)	1.3	0.4
	RGKYC (SEQ ID NO: 6)	1.3	
	RGKMC (SEQ ID NO: 7)	1.3	
20	RGKAC (SEQ ID NO: 8)		
	RGKDC (SEQ ID NO: 9)		
	RGKEC (SEQ ID NO: 10)		
	RGKFC (SEQ ID NO: 11)		
	RGKGC (SEQ ID NO: 12)		
25	RGKHC (SEQ ID NO: 13)		
	RGKKC (SEQ ID NO: 14)		
	RGKNC (SEQ ID NO: 15)		
	RGKPC (SEQ ID NO: 16)		
	RGKQC (SEQ ID NO: 17)		
30	RGKSC (SEQ ID NO: 18)		
	RGKVC (SEQ ID NO: 19)		
	RPPGF (SEQ ID NO: 39)	1.0	

- 15 -

Table II

**Inhibition of Thrombin-Induced Calcium Mobilization by Peptides**  
**of the RGKQ<sub>3</sub>C (SEQ ID NO: 43) Peptide Sublibrary**

5	Peptide	Ca <sup>2+</sup> % Inhibition	SD
	<u>At 0.2 mM Peptide</u>		
	RGKWC (SEQ ID NO: 5)	62.5	18.75
	RGKKC (SEQ ID NO: 14)	38.9	13.7
10	RGKRC (SEQ ID NO: 3)	35.7	
	RGKHC (SEQ ID NO: 13)	31.2	2.84
	RGKPC (SEQ ID NO: 16)	31.13	23.7
	RGKQC (SEQ ID NO: 17)	28	6.5
	RGKTC (SEQ ID NO: 2)	26.8	37.9
15	RGKDC (SEQ ID NO: 9)	26.7	37.7
	RGKVC (SEQ ID NO: 19)	17.3	
	RGKEC (SEQ ID NO: 10)	13.8	19.5
	RGKIC (SEQ ID NO: 4)	13.8	8.67
	RGKGC (SEQ ID NO: 12)	12.4	4.24
20	RGKLC (SEQ ID NO: 1)	8.33	11.78
	RGKMC (SEQ ID NO: 7)	7.95	11.25
	RGKAC (SEQ ID NO: 8)	5.2	
	RGKFC (SEQ ID NO: 11)	2.74	3.88
	RGKSC (SEQ ID NO: 18)	0.01	
25	RGKNC (SEQ ID NO: 15)	0	
	RGKYC (SEQ ID NO: 6)	0	

Table III

**Binding of Biotin-NAT12 Peptide from PAR1 to the**  
**RGKQ<sub>4</sub>C (SEQ ID NO: 43) Peptide Sublibrary**

5

Peptide	Level of Binding to Biotin-NAT12	SD
RGKSC (SEQ ID NO: 18)	2.2	1.5
RGKMC (SEQ ID NO: 7)	2.1	1.6
10 RGKHC (SEQ ID NO: 13)	2.1	0.7
RGKKC (SEQ ID NO: 14)	1.8	1.1
RGKFC (SEQ ID NO: 11)	1.5	1.1
RGKLC (SEQ ID NO: 1)	1.5	1.1
RGKWC (SEQ ID NO: 5)	1.3	1.4
15 RGKVC (SEQ ID NO: 19)	1.2	0.8
RGKPC (SEQ ID NO: 16)	1.2	0.8
RGKNC (SEQ ID NO: 15)	1.2	0.7
RGKGC (SEQ ID NO: 12)	1.0	0.5
RGKIC (SEQ ID NO: 4)	0.98	0.07
20 RGKYC (SEQ ID NO: 6)	0.94	0.64
RGKEC (SEQ ID NO: 10)	0.926	0.397
RGKDC (SEQ ID NO: 9)	0.82	0.36
RGKAC (SEQ ID NO: 8)	0.689	0.005
RGKTC (SEQ ID NO: 2)	0.597	0.609
25 RGKRC (SEQ ID NO: 3)	0.38	0.53
RGKQC (SEQ ID NO: 17)	0.374	0.152
RPPGF (SEQ ID NO: 39)	1.0	

Table IV

**Effect of RGDO<sub>4</sub>C (SEQ ID NO: 44) Peptide Sublibrary on  
Thrombin-Induced Platelet Aggregation**

5	Peptide	Fold Increase in Aggregation	SD
		Inhibition over RPPGF (SEQ ID NO: 39)	
	RGDWC (SEQ ID NO: 20)	31.7	41.9
	RGDFC (SEQ ID NO: 21)	25	7.1
10	RGDEC (SEQ ID NO: 22)	20	
	RGDQC (SEQ ID NO: 23)	15.8	21
	RGDMC (SEQ ID NO: 24)	15	7.1
	RGDVC (SEQ ID NO: 25)	15	7.1
	RGDHC (SEQ ID NO: 26)	14.8	14.1
15	RGDDC (SEQ ID NO: 27)	7.5	
	RGDGC (SEQ ID NO: 28)	7.5	
	RGDKC (SEQ ID NO: 29)	7.5	3.5
	RGDLC (SEQ ID NO: 30)	7.5	3.5
	RGDTC (SEQ ID NO: 31)	7.5	3.5
20	RGDNC (SEQ ID NO: 32)	5	
	RGDRC (SEQ ID NO: 33)	5	
	RGDSC (SEQ ID NO: 34)	5	
	RGDYC (SEQ ID NO: 35)	5	
	RGDIC (SEQ ID NO: 36)	3.8	1.8
25	RGDAC (SEQ ID NO: 37)		
	RGDPC (SEQ ID NO: 38)		
	RPPGF (SEQ ID NO: 39)	1	

30

Table V

**Inhibition of Thrombin-Induced Calcium Mobilization by Peptides of the****RGDO<sub>4</sub>C (SEQ ID NO: 44) Peptide Sublibrary**

	Peptide	Ca <sup>2+</sup> % Inhibition	SD
		At 0.2 mM Peptide	
	RGDNC (SEQ ID NO: 32)	44.3	5.6
10	RGDWC (SEQ ID NO: 20)	31.9	4.6
	RGDFC (SEQ ID NO: 21)	30.3	42.9
	RGDKC (SEQ ID NO: 29)	28.1	16
	RGDMC (SEQ ID NO: 24)	26.2	32.6
	RGDYC (SEQ ID NO: 35)	16.4	
15	RGDAC (SEQ ID NO: 37)	11	4.7
	RGDGC (SEQ ID NO: 28)	9.9	14
	RGDHC (SEQ ID NO: 26)	9.9	14
	RGDIC (SEQ ID NO: 36)	9.3	13.2
	RGDDC (SEQ ID NO: 27)	8.9	12.6
20	RGDQC (SEQ ID NO: 23)	8.45	11.9
	RGDPC (SEQ ID NO: 38)	4.13	5.85
	RGDVC (SEQ ID NO: 25)	2.56	3.63
	RGDEC (SEQ ID NO: 22)	1.96	2.77
	RGDLC (SEQ ID NO: 30)	0	
25	RGDRC (SEQ ID NO: 33)	0	
	RGDSC (SEQ ID NO: 34)	0	
	RGDTC (SEQ ID NO: 31)	0	

Table VI

**Binding of Biotin-NAT12 Peptide from PAR1 to the  
RGDO<sub>4</sub>C (SEQ ID NO: 44) Peptide Sublibrary**

5	Peptide	Level of Binding to	SD
		Biotin-NAT12	
	RGDSC (SEQ ID NO: 34)	1.44	0.3
	RGDGC (SEQ ID NO: 28)	1.39	0.08
10	RGDQC (SEQ ID NO: 23)	1.32	0.16
	RGDEC (SEQ ID NO: 22)	1.28	0.08
	RGDIC (SEQ ID NO: 36)	1.22	0.61
	RGDPC (SEQ ID NO: 38)	1.12	0.12
	RGDDC (SEQ ID NO: 27)	1.11	0.3
15	RGDYC (SEQ ID NO: 35)	1.05	0.089
	RGDRC (SEQ ID NO: 33)	0.99	0.4
	RGDLC (SEQ ID NO: 30)	0.98	0.19
	RGDMC (SEQ ID NO: 24)	0.87	0.27
	RGDAC (SEQ ID NO: 37)	0.8	0.26
20	RGDHC (SEQ ID NO: 26)	0.759	0.356
	RGDTC (SEQ ID NO: 31)	0.746	0.175
	RGDNC (SEQ ID NO: 25)	0.739	0.081
	RGDVC (SEQ ID NO: 25)	0.723	0.189
	RGDFC (SEQ ID NO: 21)	0.671	0.101
25	RGDKC (SEQ ID NO: 29)	0.67	0.041
	RGDWC (SEQ ID NO: 20)	0.374	0.008
	RPPGF (SEQ ID NO: 39)	1	



TABLE VII

Amino Acid	Three-letter abbreviation	One-letter symbol
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic Acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

The present invention is intended for use in individuals with acute coronary  
 5 syndromes (crescendo angina, myocardial infarction) and in individuals who have acute  
 coronary syndromes and receive percutaneous transluminal coronary angioplasty (PTCA)

with an artificial stent placement. The present invention can be used as a single agent alone or in combinations with other agents. These other agents may include any one or number of the following drugs (including all of them): standard heparin, low molecular weight heparin, aspirin, ticlopidine, clopidogrel, abciximab, tirofiban, or eptifibatide. The compounds of the present invention may be administered intravenously with the other agent(s) to treat individuals for acute coronary syndromes and during the related management. This invention also could be useful in the management of individuals with dacron grafts from peripheral bypass surgery and individuals with stents for carotid or renal artery stenosis. Agents such as those being presented here may be useful in the management of patients with transient ischemic attacks, stroke in progression, and complete stroke in the brain.

Purified peptides of the invention may be administered under circumstances where inhibition of thrombin-induced platelet activation or platelet aggregation is sought. The analogs are for use and administration to subjects experiencing platelet thrombosis from any cause, and may be used prophylactically in surgery or catheterization for insertion of artificial dacron grafts and stents to prevent reocclusion events due to platelet thrombi. Thus, the analogs may be infused into individuals to prevent strokes and cerebral edema.

The analogs may be administered by any convenient means, which will result in substantial delivery into the blood stream. Preferably the administration is parenterally. However, the administration of analogs can be executed by any means which will introduce the analogs into the bloodstream, including intravenous, intranasal, and oral administration, as well as administration via a dermal patch or rectal suppositories. Intravenous administration is presently contemplated as the preferred administration route, although intranasal administration may also be utilized.

The peptide analogs may be combined with any pharmaceutical carrier, which is physiologically acceptable to the host. The pharmaceutical composition may be compounded according to conventional pharmaceutical techniques. The carrier may be provided in a variety of forms depending on the form of preparation desired for administration. For parenteral administration, the carrier can comprise sterile water, and optionally other ingredients to aid solubility or preservative purposes. In intravenous administration, the preferred parenteral route, the analogs may be dissolved in appropriate intravenous delivery vehicles containing physiologically compatible substances, such as sterile sodium chloride having a buffered pH compatible with physiologic conditions, e.g.

saline. Injectable suspension may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.

The dosage of administration will depend on the size and weight of the patient. Those skilled in the art of infusion therapy in ICU or in interventional cardiology can  
5 derive appropriate dosages and schedules of administration to suit the specific circumstances and needs of the patient. The physiologically acceptable dosages range from about 10 to 30 mg per day per kg of body weight. In preferred intravenous administration, the dosage is 10 mg/kg body weight in 5 ml of normal saline or in any  
10 suitable vehicle given at a rate of 1 ml/min. The therapeutically optimal amounts of dosage may be determined by monitoring pre- and post- infusion platelet function by determining *ex vivo*  $\gamma$ -thrombin induced platelet aggregation and secretion, and also by measuring hemostatic parameters like activated partial thromboplastin time (APTT), prothombin time (PT), thrombin time (TT), and template bleeding time (BT).

**EDITORIAL NOTE**

**APPLICATION NUMBER - 78822/00**

**The following Sequence Listing pages 1 to 10 are part of the description. The claims pages follow on pages 24 to 32.**

## SEQUENCE LISTING

<110> Schmaier, Alvin H.  
Hasan, Ahmed A.K.

<120> PEPTIDE ANALOGS AS SELECTIVE INHIBITORS OF THROMBIN  
ACTIVATION OF PROTEASE ACTIVATED RECEPTOR 1

<130> 32921-165663

<150> US 09/375,808  
<151> 1999-08-17

<160> 46

<170> PatentIn Ver. 2.0

<210> 1  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 1  
Arg Gly Lys Leu Cys  
1 5

<210> 2  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 2  
Arg Gly Lys Thr Cys  
1 5

<210> 3  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 3  
Arg Gly Lys Arg Cys  
1 5

<210> 4  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic

## peptide

<400> 4  
Arg Gly Lys Ile Cys  
1 5

<210> 5  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 5  
Arg Gly Lys Trp Cys  
1 5

<210> 6  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 6  
Arg Gly Lys Tyr Cys  
1 5

<210> 7  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 7  
Arg Gly Lys Met Cys  
1 5

<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 8  
Arg Gly Lys Ala Cys  
1 5

<210> 9  
<211> 5  
<212> PRT

<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence: synthetic peptide  
<400> 9  
Arg Gly Lys Asp Cys  
1 5  
  
<210> 10  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence: synthetic peptide  
<400> 10  
Arg Gly Lys Glu Cys  
1 5  
  
<210> 11  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence: synthetic peptide  
<400> 11  
Arg Gly Lys Phe Cys  
1 5  
  
<210> 12  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence: synthetic peptide  
<400> 12  
Arg Gly Lys Gly Cys  
1 5  
  
<210> 13  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence: synthetic peptide  
<400> 13  
Arg Gly Lys His Cys  
1 5

<210> 14  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 14  
Arg Gly Lys Lys Cys  
1 5

<210> 15  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 15  
Arg Gly Lys Asn Cys  
1 5

<210> 16  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 16  
Arg Gly Lys Pro Cys  
1 5

<210> 17  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 17  
Arg Gly Lys Gln Cys  
1 5

<210> 18  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide



<400> 18  
Arg Gly Lys Ser Cys  
1 5

<210> 19  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 19  
Arg Gly Lys Val Cys  
1 5

<210> 20  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 20  
Arg Gly Asp Trp Cys  
1 5

<210> 21  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 21  
Arg Gly Asp Phe Cys  
1 5

<210> 22  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
peptide

<400> 22  
Arg Gly Asp Glu Cys  
1 5

<210> 23  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 23  
Arg Gly Asp Gln Cys  
1 5

<210> 24  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 24  
Arg Gly Asp Met Cys  
1 5

<210> 25  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 25  
Arg Gly Asp Val Cys  
1 5

<210> 26  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 26  
Arg Gly Asp His Cys  
1 5

<210> 27  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 27  
Arg Gly Asp Asp Cys  
1 5

<210> 28

<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 28  
Arg Gly Asp Gly Cys  
1 5

<210> 29  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 29  
Arg Gly Asp Lys Cys  
1 5

<210> 30  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 30  
Arg Gly Asp Leu Cys  
1 5

<210> 31  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 31  
Arg Gly Asp Thr Cys  
1 5

<210> 32  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic peptide

<400> 32  
Arg Gly Asp Asn Cys

1 5

<210> 33  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 33  
Arg Gly Asp Arg Cys  
1 5

<210> 34  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 34  
Arg Gly Asp Ser Cys  
1 5

<210> 35  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 35  
Arg Gly Asp Tyr Cys  
1 5

<210> 36  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic  
peptide  
  
<400> 36  
Arg Gly Asp Ile Cys  
1 5

<210> 37  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: synthetic

## peptide

&lt;400&gt; 37

Arg Gly Asp Ala Cys  
1 5

&lt;210&gt; 38

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
peptide

&lt;400&gt; 38

Arg Gly Asp Pro Cys  
1 5

&lt;210&gt; 39

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
peptide

&lt;400&gt; 39

Arg Pro Pro Gly Phe  
1 5

&lt;210&gt; 40

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

Arg Pro Pro Gly Phe Ser Pro Phe Arg  
1 5

&lt;210&gt; 41

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

Asn Ala Thr Leu Asp Pro Arg Ser Phe Leu Leu Arg  
1 5 10

&lt;210&gt; 42

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
peptide formula

&lt;220&gt;

&lt;223&gt; Xaa at position 4 may be any naturally occurring

amino acid excluding Asp and Cys

<400> 42

Arg Gly Lys Xaa Cys  
1 5

<210> 43

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
peptide formula

<220>

<223> Xaa at position 4 may be any naturally occurring  
amino acid excluding Cys

<400> 43

Arg Gly Lys Xaa Cys  
1 5

<210> 44

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
peptide formula

<220>

<223> Xaa at position 4 may be any naturally occurring  
amino acid excluding Cys

<400> 44

Arg Gly Asp Xaa Cys  
1 5

<210> 45

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
peptide

<400> 45

Arg Pro Pro Gly  
1

<210> 46

<211> 6

<212> PRT

<213> Homo sapiens

<400> 46

Ser Phe Leu Leu Arg Asn  
1 5

**THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:**

1. A method for inhibiting thrombin activation in a human cell expressing PAR1, comprising:

providing a mixture comprising thrombin and a human cell expressing PAR1, wherein

5 the concentration of thrombin is effective to induce stimulus-response coupling within the cell;

contacting the mixture with an amount of a compound comprising at

least one segment with the amino acid sequence of the formulae selected

from the group consisting of Formula I and Formula II,

10 wherein Formula I is

Arg-Gly-Lys-Z<sub>4</sub>-Cys (SEQ ID NO: 43)

wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine; and

wherein Formula II is

Arg-Gly-Asp-Z<sub>4</sub>-Cys (SEQ ID NO: 44)

15 wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine; and

wherein said compound comprises at most 10 amino acids in sequence.

2. The method of claim 1, wherein thrombin is selected from the group consisting of alpha thrombin, gamma thrombin, and admixtures thereof.

3. The method of claim 1 or claim 2, which comprises inhibiting thrombin induced platelet aggregation wherein said thrombin is selected from the group consisting of alpha-thrombin and gamma-thrombin.

4. The method of claim 3, wherein said segment is selected from the group consisting of:

Arg-Gly-Lys-Leu-Cys (SEQ ID NO: 1);

Arg-Gly-Lys-Thr-Cys (SEQ ID NO: 2);

Arg-Gly-Lys-Arg-Cys (SEQ ID NO: 3);

Arg-Gly-Lys-Ile-Cys (SEQ ID NO: 4);

Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5);

Arg-Gly-Lys-Tyr-Cys (SEQ ID NO: 6); and

Arg-Gly-Lys-Met-Cys (SEQ ID NO: 7).

5. The method of claim 3, wherein said segment is selected from the group consisting of:

Arg-Gly-Asp-Trp-Cys (SEQ ID NO: 20);  
Arg-Gly-Asp-Phe-Cys (SEQ ID NO: 21);  
Arg-Gly-Asp-Glu-Cys (SEQ ID NO: 22);  
Arg-Gly-Asp-Gln-Cys (SEQ ID NO: 23);  
Arg-Gly-Asp-Met-Cys (SEQ ID NO: 24);  
Arg-Gly-Asp-Val-Cys (SEQ ID NO: 25);  
Arg-Gly-Asp-His-Cys (SEQ ID NO: 26);  
Arg-Gly-Asp-Asp-Cys (SEQ ID NO: 27);  
Arg-Gly-Asp-Gly-Cys (SEQ ID NO: 28);  
Arg-Gly-Asp-Lys-Cys (SEQ ID NO: 29);  
Arg-Gly-Asp-Leu-Cys (SEQ ID NO: 30); and  
Arg-Gly-Asp-Thr-Cys (SEQ ID NO: 31).

6. The method of any one of claims 1 to 5, which comprises inhibiting thrombin induced calcium mobilization in fibroblasts.

7. The method of claim 6, wherein said segment is selected from the group consisting of:

Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5);  
Arg-Gly-Lys-Lys-Cys (SEQ ID NO: 14);  
Arg-Gly-Lys-Arg-Cys (SEQ ID NO: 3);  
Arg-Gly-Lys-His-Cys (SEQ ID NO: 13);  
Arg-Gly-Lys-Pro-Cys (SEQ ID NO: 16);  
Arg-Gly-Lys-Gln-Cys (SEQ ID NO: 17);  
Arg-Gly-Lys-Thr-Cys (SEQ ID NO: 2); and  
Arg-Gly-Lys-Asp-Cys (SEQ ID NO: 9).

8. The method of claim 6, wherein said segment is selected from the group consisting of:

Arg-Gly-Asp-Asn-Cys (SEQ ID NO: 32);  
Arg-Gly-Asp-Trp-Cys (SEQ ID NO: 20);  
Arg-Gly-Asp-Phe-Cys (SEQ ID NO: 21);

HAValma\Keep\Specifications\08822-00.doc 22/02/02



Arg-Gly-Asp-Lys-Cys (SEQ ID NO: 29);  
Arg-Gly-Asp-Met-Cys (SEQ ID NO: 24);  
Arg-Gly-Asp-Tyr-Cys (SEQ ID NO: 35); and  
Arg-Gly-Asp-Ala-Cys (SEQ ID NO: 37).

5

9. The method of any one of claims 1 to 8, wherein said compound comprises at most 5 amino acids in sequence.

10. The method of any one of claims 1 to 9, wherein said cell expressing PAR1 is selected from the group consisting of platelets, endothelial cells, brain cells, fibroblasts, and smooth muscle cells.

11. A method of binding a compound to biotinylated-peptide NATLDPRSFLLR (SEQ ID NO: 41) (biotin-NAT12), comprising:

15  
20

providing a compound comprising at least one segment with the amino acid sequence of the formulae selected from the group consisting of Formula I and Formula II,

wherein Formula I is

Arg-Gly-Lys-Z<sub>4</sub>-Cys (SEQ ID NO: 43)

wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine; and

wherein Formula II is

Arg-Gly-Asp-Z<sub>4</sub>-Cys (SEQ ID NO: 44)

wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine;

wherein said compound comprises at most 10 amino acids in sequence; and

incubating biotinylated-peptide NATLDPRSFLLR (SEQ ID NO: 41) (biotin-NAT12) with said compound.

25

12. The method of claim 11, wherein said segment is selected from the group consisting of:

30

Arg-Gly-Lys-Ser-Cys (SEQ ID NO: 18);  
Arg-Gly-Lys-Met-Cys (SEQ ID NO: 7);  
Arg-Gly-Lys-His-Cys (SEQ ID NO: 13);  
Arg-Gly-Lys-Lys-Cys (SEQ ID NO: 14);  
Arg-Gly-Lys-Phe-Cys (SEQ ID NO: 11);  
Arg-Gly-Lys-Leu-Cys (SEQ ID NO: 1);

H:\Valm\Keep\Specifications\08022-00.doc 22/02/02

Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5); and

Arg-Gly-Lys-Val-Cys (SEQ ID NO: 19).

13. The method of claim 11, wherein said segment is selected from the group  
5 consisting of:

Arg-Gly-Asp-Ser-Cys (SEQ ID NO: 34);

Arg-Gly-Asp-Gly-Cys (SEQ ID NO: 28);

Arg-Gly-Asp-Gln-Cys (SEQ ID NO: 23);

Arg-Gly-Asp-Glu-Cys (SEQ ID NO: 22);

10 Arg-Gly-Asp-Ile-Cys (SEQ ID NO: 36);

Arg-Gly-Asp-Pro-Cys (SEQ ID NO: 38);

Arg-Gly-Asp-Asp-Cys (SEQ ID NO: 27); and

Arg-Gly-Asp-Tyr-Cys (SEQ ID NO: 35).

15  
20

14. A method for inhibiting thrombin activation in a sample comprising blood platelets,  
comprising:

providing a solution comprising thrombin and blood platelets, wherein the  
concentration of thrombin is effective to cause platelet aggregation;

contacting the blood sample with an amount of a compound comprising at  
least one segment with the amino acid sequence of the formulae selected  
from the group consisting of Formula I and Formula II,

wherein Formula I is

Arg-Gly-Lys-Z<sub>4</sub>-Cys (SEQ ID NO: 43)

wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding  
cysteine; and

wherein Formula II is

Arg-Gly-Asp-Z<sub>4</sub>-Cys (SEQ ID NO: 44)

wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine; and  
wherein said compound comprises at most 10 amino acids in sequence.

25  
30

15. The method of claim 14, wherein thrombin is selected from the group consisting of  
alpha-thrombin, gamma-thrombin, and admixtures thereof.

16. The method of claims 13 or claim 14, which comprises inhibiting thrombin induced platelet aggregation wherein said thrombin is selected from the group consisting of alpha-thrombin and gamma-thrombin.

5 17. The method of any one of claims 14 to 16, wherein said segment is selected from the group consisting of:

Arg-Gly-Lys-Leu-Cys (SEQ ID NO: 1);  
Arg-Gly-Lys-Thr-Cys (SEQ ID NO: 2);  
Arg-Gly-Lys-Arg-Cys (SEQ ID NO: 3);  
10 Arg-Gly-Lys-Ile-Cys (SEQ ID NO: 4);  
Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5);  
Arg-Gly-Lys-Tyr-Cys (SEQ ID NO: 6); and  
Arg-Gly-Lys-Met-Cys (SEQ ID NO: 7).

15 18. The method of any one of claims 14 to 16, wherein said segment is selected from the group consisting of:

Arg-Gly-Asp-Trp-Cys (SEQ ID NO: 20);  
Arg-Gly-Asp-Phe-Cys (SEQ ID NO: 21);  
Arg-Gly-Asp-Glu-Cys (SEQ ID NO: 22);  
Arg-Gly-Asp-Gln-Cys (SEQ ID NO: 23);  
Arg-Gly-Asp-Met-Cys (SEQ ID NO: 24);  
Arg-Gly-Asp-Val-Cys (SEQ ID NO: 25);  
Arg-Gly-Asp-His-Cys (SEQ ID NO: 26);  
Arg-Gly-Asp-Asp-Cys (SEQ ID NO: 27);  
Arg-Gly-Asp-Gly-Cys (SEQ ID NO: 28);  
Arg-Gly-Asp-Lys-Cys (SEQ ID NO: 29);  
Arg-Gly-Asp-Leu-Cys (SEQ ID NO: 30); and  
Arg-Gly-Asp-Thr-Cys (SEQ ID NO: 31).

20 19. The method of any one of claims 14 to 18, wherein said compound comprises at most 5 amino acids in sequence.

20. A compound comprising at least one segment with the amino acid sequence of the formulae selected from the group consisting of Formula I and Formula II, wherein Formula I is

Arg-Gly-Lys-Z<sub>4</sub>-Cys (SEQ ID NO: 42)

5 wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine or asparagine; and

wherein Formula II is

Arg-Gly-Asp-Z<sub>4</sub>-Cys (SEQ ID NO: 44)

wherein Z<sub>4</sub> is any naturally occurring amino acid, excluding cysteine; and

10 wherein the compound contains at most 10 amino acids in sequence.

21. The compound of claim 20, wherein said segment of Formula I is selected from the group consisting of:

15  
20

Arg-Gly-Lys-Leu-Cys (SEQ ID NO: 1);  
Arg-Gly-Lys-Thr-Cys (SEQ ID NO: 2);  
Arg-Gly-Lys-Arg-Cys (SEQ ID NO: 3);  
Arg-Gly-Lys-Ile-Cys (SEQ ID NO: 4);  
Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5);  
Arg-Gly-Lys-Tyr-Cys (SEQ ID NO: 6); and  
Arg-Gly-Lys-Met-Cys (SEQ ID NO: 7);

and wherein the segment of Formula II is selected from the group consisting of:

25

Arg-Gly-Asp-Trp-Cys (SEQ ID NO: 20);  
Arg-Gly-Asp-Phe-Cys (SEQ ID NO: 21);  
Arg-Gly-Asp-Glu-Cys (SEQ ID NO: 22);  
Arg-Gly-Asp-Gln-Cys (SEQ ID NO: 23);  
Arg-Gly-Asp-Met-Cys (SEQ ID NO: 24);  
Arg-Gly-Asp-Val-Cys (SEQ ID NO: 25);  
Arg-Gly-Asp-His-Cys (SEQ ID NO: 26);  
Arg-Gly-Asp-Asp-Cys (SEQ ID NO: 27);  
Arg-Gly-Asp-Gly-Cys (SEQ ID NO: 28);  
Arg-Gly-Asp-Lys-Cys (SEQ ID NO: 29);  
Arg-Gly-Asp-Leu-Cys (SEQ ID NO: 30); and  
Arg-Gly-Asp-Thr-Cys (SEQ ID NO: 31).

30

22. The compound of claim 20, wherein the segment Formula I is selected from the group consisting of:

- 5 Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5);  
Arg-Gly-Lys-Lys-Cys (SEQ ID NO: 14);  
Arg-Gly-Lys-Arg-Cys (SEQ ID NO: 3);  
Arg-Gly-Lys-His-Cys (SEQ ID NO: 13);  
Arg-Gly-Lys-Pro-Cys (SEQ ID NO: 16);  
Arg-Gly-Lys-Gln-Cys (SEQ ID NO: 17); and  
Arg-Gly-Lys-Thr-Cys (SEQ ID NO: 2);

10

and wherein the segment of Formula II is selected from the group consisting of:

- Arg-Gly-Asp-Asn-Cys (SEQ ID NO: 32);  
Arg-Gly-Asp-Trp-Cys (SEQ ID NO: 20);  
Arg-Gly-Asp-Phe-Cys (SEQ ID NO: 21);  
15 Arg-Gly-Asp-Lys-Cys (SEQ ID NO: 29);  
Arg-Gly-Asp-Met-Cys (SEQ ID NO: 24);  
Arg-Gly-Asp-Tyr-Cys (SEQ ID NO: 35); and  
Arg-Gly-Asp-Ala-Cys (SEQ ID NO: 37).

20 23. The compound of claim 20, wherein the segment of Formula I is selected from the group consisting of:

- Arg-Gly-Lys-Ser-Cys (SEQ ID NO: 18);  
Arg-Gly-Lys-Met-Cys (SEQ ID NO: 7);  
Arg-Gly-Lys-His-Cys (SEQ ID NO: 13);  
25 Arg-Gly-Lys-Lys-Cys (SEQ ID NO: 14);  
Arg-Gly-Lys-Phe-Cys (SEQ ID NO: 11);  
Arg-Gly-Lys-Leu-Cys (SEQ ID NO: 1);  
Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5); and  
Arg-Gly-Lys-Val-Cys (SEQ ID NO: 19);

10

and wherein the segment of Formula II is selected from the group consisting of:

- Arg-Gly-Asp-Ser-Cys (SEQ ID NO: 34);  
Arg-Gly-Asp-Gly-Cys (SEQ ID NO: 28);  
Arg-Gly-Asp-Gln-Cys (SEQ ID NO: 23);

Arg-Gly-Asp-Glu-Cys (SEQ ID NO: 22);  
Arg-Gly-Asp-Ile-Cys (SEQ ID NO: 36);  
Arg-Gly-Asp-Pro-Cys (SEQ ID NO: 38);  
Arg-Gly-Asp-Asp-Cys (SEQ ID NO: 27); and  
Arg-Gly-Asp-Tyr-Cys (SEQ ID NO: 35).

5

24. The compound of claim 20, wherein the compound comprises at most 5 amino acids in sequence.

10

25. The compound of claim 20, wherein the segment is Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5).

26. The compound of claim 20, wherein the segment is Arg-Gly-Asp-Trp-Cys (SEQ ID NO: 20).

15  
20

27. The method of claim 6, wherein the segment is Arg-Gly-Lys-Trp-Cys (SEQ ID NO: 5).

28. The method of claim 16, wherein the segment is Arg-Gly-Asp-Trp-Cys (SEQ ID NO: 20).

25

29. A method of preventing thrombosis, wherein thrombosis is defined as occlusion of a vessel due to formation of a platelet-rich, fibrin-rich, or a mixed platelet-fibrin thrombus, and wherein the method comprises the method of any one of claims 1 to 10, 14 to 19, 27 and 28.

30

30. A composition comprising a compound according to any one of claims 20 to 25, together with a pharmaceutically acceptable carrier.

30

31. Use of a compound according to any one of claims 20 to 25 in the treatment or prevention of thrombosis.

32. Use of a compound according to any one of claims 20 to 25 in the manufacture of a medicament for the treatment or prevention of thrombosis.

33. A method according to any one of claims 1, 11, 14 and 29, substantially as herein described with reference to the examples and drawings.

34. A compound according to claim 20, substantially as herein described with  
5 reference to the examples and drawings.

Dated this 22nd day of February 2002

THROMGEN, INC.

By their Patent Attorneys

10 GRIFFITH HACK

Fellows Institute of Patent and

Trade Mark Attorneys of Australia


15  
20  
25  
30  
35

40  
45  
50

55  
60

22. 2.02 70022

1/9





22.00 78033

2/9




FIG. 2B

FIG. 2A

02.002 78802




FIG. 2C




FIG. 2D

22.089 78822

4/9





FIG. 2E

FIG. 2F

02.002 78802



70nM THROMBIN

FIG. 3A



1mM RPPGF

FIG. 3B



0.5mM RPPGF

FIG. 3C



0.2mM RGDWC

FIG. 3D



0.1mM RGDWC

FIG. 3E




0.05mM RGDWC

FIG. 3F



0.025mM RGDWC

FIG. 3G



0.0125mM RGDWC

FIG. 3H



0.00625mM RGDWC

FIG. 3I

6/9




FIG. 4A




FIG. 4B




FIG. 4C





FIG. 4D


22 202 70802




4.5μM ADP  
FIG. 5A



1mM RPPGF  
FIG. 5B



1mM MaP<sub>4</sub>  
FIG. 5C



0.5mM MaP<sub>4</sub>  
FIG. 5D



1mM RGKWC  
FIG. 5E




1mM RGDWC  
FIG. 5F




0.5mM RGDWC  
FIG. 5G



0.25mM RGDWC  
FIG. 5H



0.125mM RGDWC  
FIG. 5I



0.0625mM RGDWC  
FIG. 5J




FIG. 6